FDA warns compounder
- The FDA issued a warning letter to New Life after inspectors say they were denied access to parts of its facility. - The facility reportedly produced semaglutide and tirzepatide compounded products under scrutiny by regulators. - The enforcement action signals tougher federal oversight of lower-cost or compounded GLP‑1 supply, according to BioSpace. (biospace.com)
The Food and Drug Administration warned New Life Pharma after inspectors said the company blocked access to parts of a New Jersey plant making semaglutide and tirzepatide injections. (biospace.com) The agency’s April 14, 2026 warning letter says FDA inspected New Life’s facility at 265 Livingston Street in Northvale, New Jersey, from February 3 to February 13, 2026. FDA said the company’s “Semaglutide Sterile Multi-Dose Vial” and “Tirzepatide Sterile Multi-Dose Vial” were unapproved new drugs and were also misbranded because the firm did not properly register or list them. (ciopharma.com) FDA also said New Life’s manufacturing controls did not meet current good manufacturing practice rules, the baseline quality rules for drug plants, and that the drugs were adulterated under federal law. The letter says investigators documented that the firm “delayed, denied, limited, and/or refused” inspection, a separate violation for a drug manufacturer. (ciopharma.com) Semaglutide and tirzepatide are the active ingredients in blockbuster diabetes and obesity drugs sold by Novo Nordisk and Eli Lilly. Compounded versions spread during shortages, when pharmacies and outsourcing facilities could legally fill some gaps in supply under FDA’s compounding rules. (biospace.com) (fda.gov) That shortage window has narrowed. FDA said its enforcement discretion for state-licensed pharmacy and physician compounding of tirzepatide ended after a March 5, 2025 court ruling, and the comparable period for semaglutide compounding ended after an April 24, 2025 court ruling, with a later May 22, 2025 deadline for certain outsourcing facilities. (fda.gov) FDA has separately warned that unapproved or compounded glucagon-like peptide-1 drugs do not go through the agency’s premarket review for safety, effectiveness, or quality. The agency says compounded versions should be used only when a patient’s medical needs cannot be met by an FDA-approved drug or when the approved drug is not commercially available. (fda.gov) The New Life letter fits a wider 2026 enforcement push. Regulatory Affairs Professionals Society reported on April 7 that FDA had published several new warning letters to companies marketing unapproved GLP-1 and related products, adding to dozens of similar letters issued over the past year. (raps.org) FDA warning letters are not final court findings, and the agency says companies can continue interacting with regulators after a letter is posted. New Life was given 15 working days to respond in writing, according to reporting on the letter, and FDA’s public warning-letter page notes that a company’s regulatory status can change after further exchanges with the agency. (biotech-insider.com) (fda.gov)
